DYN - NASDAQ
Dyne Therapeutics, Inc.
$17.99
-3.4%Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
At a Glance
Live SnapshotDyne Therapeutics, Inc. Management Team
Ms. Johanna Friedl-Naderer
Chief Commercial Officer
Compensation
$748,769
Mr. James P. Bilotta M.B.A.
Chief Digital & Information Officer
Mr. John G. Cox M.B.A.
Chief Executive Officer, President & Director
Compensation
$1,028,185
Mr. Erick J. Lucera C.F.A., CPA
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer
Ms. Lucia Celona
Chief Human Resource Officer
Dr. Oxana Beskrovnaya Ph.D.
Chief Innovation Officer
Compensation
$719,521
Dr. Douglas Kerr M.B.A., M.D., Ph.D.
Chief Medical Officer
Compensation
$745,640
Dr. Ranjan Batra Ph.D.
Chief Scientific Officer
Dr. Rajesh Manchanda Ph.D.
Chief Technical Officer
Mr. Daniel Wilson
Senior Vice President & Head of Legal
Dyne Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.11M and sold $23.94M worth of DYN shares, resulting in $22.84M of net selling activity.
3 Months
11.5K
197.26K
1.2M
23.63M
-23.4M
-$23.43M
3-6 Months
0
0.00
3.8K
56.38K
-56K
-$56K
6-9 Months
0
0.00
3.7K
76.37K
-76K
-$76K
9-12 Months
100.0K
911.00K
13.7K
182.10K
+729K
+$729K
Top Buyers
Cox John
Director, Officer: Ceo & President
$911K
Posner Brian S
Director
$197K
Top Sellers
Kersten Dirk
Director
$14.56M
Rhodes Jason P
Director
$8.84M
Cox John
Director, Officer: Ceo & President
$246K
Kerr Douglas
Officer: Chief Medical Officer
$137K
Lucera Erick
Officer: Chief Financial Officer
$133K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $22.84M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
DYN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 15, 2025 | May 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 07, 2023 | May 24, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 22, 2022 | June 03, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 14, 2021 | May 26, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.